TY - JOUR
T1 - Identification of a CD4+ T cell line with Treg-like activity
AU - Ho, Thai H.
AU - Pfeffer, Kirsten
AU - Weiss, Glen J.
AU - Ruiz, Yvette
AU - Lake, Douglas F.
N1 - Funding Information:
THH has received research funding from Novartis and has served on advisory boards for Exelixis, Genentech, EMD-Serono, Ipsen, Cardinal Health, Surface Therapeutics, and Pfizer. GJW is an employee of SOTIO and former employee of Unum Therapeutics-both outside of submitted work, reports personal fees from MiRanostics Consulting, Paradigm, Angiex, IBEX Medical Analytics, Spring Bank Pharmaceuticals, Pfizer, IDEA Pharma, GLG Council, Guidepoint Global, Ignyta, Circulogene, Genomic Health-all outside this submitted work; has received travel reimbursement from Cambridge HealthTech Institute, GlaxoSmith Kline, and Tesaro-outside of this submitted work; had ownership interest in MiRanostics Consulting, Unum Therapeutics, Exact Sciences, and Circulogene-outside the submitted work; and has a patent for methods and kits to predict prognostic and therapeutic outcome in small cell lung cancer issued, outside the submitted work. The other authors declare no conflicts of interest.
Funding Information:
Support was provided by Ken and Valarie Dabrowski Foundation, Gloria A. and Thomas J. Dutson Jr. Kidney Research Endowment, Novartis, and an ASU-Mayo Seed grant to THH and DFL. THH is supported by the Gerstner Family Career Development Award and the National Cancer Institute (R01CA224917). Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the funding agencies. The funding agencies had no role in the study design. THH, GJW and DFL designed and interpreted all experiments. YR and KP performed all experiments. THH has received research funding from Novartis and has served on advisory boards for Exelixis, Genentech, EMD-Serono, Ipsen, Cardinal Health, Surface Therapeutics, and Pfizer. GJW is an employee of SOTIO and former employee of Unum Therapeutics-both outside of submitted work, reports personal fees from MiRanostics Consulting, Paradigm, Angiex, IBEX Medical Analytics, Spring Bank Pharmaceuticals, Pfizer, IDEA Pharma, GLG Council, Guidepoint Global, Ignyta, Circulogene, Genomic Health-all outside this submitted work; has received travel reimbursement from Cambridge HealthTech Institute, GlaxoSmith Kline, and Tesaro-outside of this submitted work; had ownership interest in MiRanostics Consulting, Unum Therapeutics, Exact Sciences, and Circulogene-outside the submitted work; and has a patent for methods and kits to predict prognostic and therapeutic outcome in small cell lung cancer issued, outside the submitted work. The other authors declare no conflicts of interest.
Funding Information:
Support was provided by Ken and Valarie Dabrowski Foundation, Gloria A. and Thomas J. Dutson Jr. Kidney Research Endowment, Novartis, and an ASU-Mayo Seed grant to THH and DFL. THH is supported by the Gerstner Family Career Development Award and the National Cancer Institute (R01CA224917). Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the funding agencies. The funding agencies had no role in the study design.
Publisher Copyright:
© 2022 American Society for Histocompatibility and Immunogenetics
PY - 2022/4
Y1 - 2022/4
N2 - Regulatory T cells (Tregs) suppress adaptive immunity and inflammation. Although they play a role in suppressing anti-tumor responses, development of therapeutics that target Tregs is limited by their low abundance, heterogeneity, and lack of specific cell surface markers. We isolated human PBMC-derived CD4+ CD25high Foxp3+ Tregs and demonstrate they suppress stimulated CD4+ PBMCs in a cell contact-dependent manner. Because it is not possible to functionally characterize cells after intracellular Foxp3 staining, we identified a human T cell line, MoT, as a model of human Foxp3+ Tregs. Unlike Jurkat T cells, MoT cells share common surface markers consistent with human PBMC-derived Tregs such as: CD4, CD25, GITR, LAG-3, PD-L1, CCR4. PBMC-derived Tregs and MoT cells, but not Jurkat cells, inhibited proliferation of human CD4+ PBMCs in a ratio-dependent manner. Transwell membrane separation prevented suppression of stimulated CD4+ PBMC proliferation by MoT cells and Tregs, suggesting cell–cell contact is required for suppressive activity. Blocking antibodies against PD-L1, LAG-3, GITR, CCR4, HLA-DR, or CTLA-4 did not reverse the suppressive activity. We show that human PBMC-derived Tregs and MoT cells suppress stimulated CD4+ PBMCs in a cell contact-dependent manner, suggesting that a Foxp3+ Treg population suppresses immune responses by an uncharacterized cell contact-dependent mechanism.
AB - Regulatory T cells (Tregs) suppress adaptive immunity and inflammation. Although they play a role in suppressing anti-tumor responses, development of therapeutics that target Tregs is limited by their low abundance, heterogeneity, and lack of specific cell surface markers. We isolated human PBMC-derived CD4+ CD25high Foxp3+ Tregs and demonstrate they suppress stimulated CD4+ PBMCs in a cell contact-dependent manner. Because it is not possible to functionally characterize cells after intracellular Foxp3 staining, we identified a human T cell line, MoT, as a model of human Foxp3+ Tregs. Unlike Jurkat T cells, MoT cells share common surface markers consistent with human PBMC-derived Tregs such as: CD4, CD25, GITR, LAG-3, PD-L1, CCR4. PBMC-derived Tregs and MoT cells, but not Jurkat cells, inhibited proliferation of human CD4+ PBMCs in a ratio-dependent manner. Transwell membrane separation prevented suppression of stimulated CD4+ PBMC proliferation by MoT cells and Tregs, suggesting cell–cell contact is required for suppressive activity. Blocking antibodies against PD-L1, LAG-3, GITR, CCR4, HLA-DR, or CTLA-4 did not reverse the suppressive activity. We show that human PBMC-derived Tregs and MoT cells suppress stimulated CD4+ PBMCs in a cell contact-dependent manner, suggesting that a Foxp3+ Treg population suppresses immune responses by an uncharacterized cell contact-dependent mechanism.
KW - CFSE T cell suppression assays
KW - Contact-dependent suppression
KW - Regulatory T cells
UR - http://www.scopus.com/inward/record.url?scp=85123727569&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123727569&partnerID=8YFLogxK
U2 - 10.1016/j.humimm.2022.01.008
DO - 10.1016/j.humimm.2022.01.008
M3 - Article
C2 - 35094878
AN - SCOPUS:85123727569
SN - 0198-8859
VL - 83
SP - 281
EP - 294
JO - Human Immunology
JF - Human Immunology
IS - 4
ER -